EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting H3K27-Altered Diffuse Midline Glioma with Combined MEK and HDAC Inhibition: Clinical Response and In Vitro Validation

Robert T. Galvin, Alex Larsson, Meghna Saxena, Garrett Fitzpatrick, David Nascene, Patrick C. Graupman, Clay Hoerig, Elizabeth C. Neil, Grace Tobin, Christopher L. Moertel, David A. Largaespada, Kyle B. Williams

Current Oncology · 10.11.2026 · 33 (11) · 695

DOI: 10.3390/curroncol33110695 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, online erschienen am 10.11.2026. Verfasst von Robert T. Galvin und 11 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Histone H3 K27-altered diffuse midline gliomas (DMGs) have poor outcomes and are characterized by global loss of H3K27 trimethylation (H3K27me3). Evidence from other H3K27me3-deficient tumors suggests a potential vulnerability to combined histone deacetylase (HDAC) and MEK inhibition. We examined a clinical experience with this combination and tested its activity in glioma models.

Methods

We reviewed the course of an 11-year-old with neurofibromatosis type 1 and a thoracic spinal DMG treated with selumetinib and vorinostat after gross-total resection, without upfront radiotherapy. In post hoc viability assays, we tested HDAC and MEK inhibition in two H3K27M-mutant glioma lines, an isogenic K27-rescued derivative, and two H3-wildtype lines. Combination benefit was measured as the reduction in area under the viability curve relative to vorinostat alone.

Results

The patient experienced 22 months of radiotherapy-free, progression-free survival before recurrence, with a postoperative enhancing focus resolving during treatment. Treatment was associated with grade 1 diarrhea and dermatitis. In vitro, combination benefit was greater in the H3K27M-mutant lines than in the H3-wildtype lines (mean difference, 13.2; 95% confidence interval, 8.1–18.3; p < 0.001). Benefit was also greater in DIPG17 than in its K27-rescued derivative (mean difference, 22.4; 95% confidence interval, 10.1–34.7; p = 0.015).

Conclusions

This clinical observation and the post hoc validation experiments support prospective study of H3K27me3 loss as a candidate biomarker for combined HDAC and MEK inhibition.

Zitieren

APA

Galvin, R. T., Larsson, A., Saxena, M., Fitzpatrick, G., Nascene, D., Graupman, P. C., Hoerig, C., Neil, E. C., Tobin, G., Moertel, C. L., Largaespada, D. A., & Williams, K. B. (2026). Targeting H3K27-Altered Diffuse Midline Glioma with Combined MEK and HDAC Inhibition: Clinical Response and In Vitro Validation. Current Oncology, 33(11), 695. https://doi.org/10.3390/curroncol33110695

Vancouver

Galvin RT, Larsson A, Saxena M, Fitzpatrick G, Nascene D, Graupman PC, et al. Targeting H3K27-Altered Diffuse Midline Glioma with Combined MEK and HDAC Inhibition: Clinical Response and In Vitro Validation. Current Oncology. 2026;33(11):695. doi:10.3390/curroncol33110695

BibTeX
@article{Galvin2026,
  author = {Galvin, Robert T. and Larsson, Alex and Saxena, Meghna and Fitzpatrick, Garrett and Nascene, David and Graupman, Patrick C. and Hoerig, Clay and Neil, Elizabeth C. and Tobin, Grace and Moertel, Christopher L. and Largaespada, David A. and Williams, Kyle B.},
  title = {Targeting H3K27-Altered Diffuse Midline Glioma with Combined MEK and HDAC Inhibition: Clinical Response and In Vitro Validation},
  journal = {Current Oncology},
  year = {2026},
  volume = {33},
  number = {11},
  pages = {695},
  doi = {10.3390/curroncol33110695}
}
Kostenlos starten →